Pumpinheart

Executive Summary

Pumpinheart is a Dublin-based medical device spinout from the Royal College of Surgeons in Ireland (RCSI), founded in 2015 and currently in the pre-clinical stage. The company is developing the PReduction device, a novel implantable diastolic pump designed to treat Heart Failure with preserved Ejection Fraction (HFpEF), a condition with limited treatment options and high morbidity. The device aims to reduce left atrial pressure during diastole, potentially improving patient outcomes and reducing hospitalizations. As an early-stage private company, Pumpinheart has not yet disclosed total funding or valuation, and its technology remains in preclinical development. The company represents a high-risk, high-reward opportunity in the cardiovascular medical device space, with a technology that addresses a significant unmet need. Conviction is moderate given the early stage and lack of clinical data, but the strong scientific foundation and specific disease focus warrant attention.

Upcoming Catalysts (preview)

• Q4 2026Preclinical study results in animal model60% success
• Q2 2027First-in-human (FIM) trial initiation40% success
• Q1 2027Series A funding round completion70% success